Leukemia, Chronic Myelogenous

Leukemia, Chronic Myelogenous is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Description

  • Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid precursors in the bone marrow with continuing differentiation into mature granulocytes.
  • Hallmark of CML is Philadelphia chromosome (translocation t[9;22]).
  • Natural history of the disease evolves in three clinical phases: a chronic phase, an accelerated phase, and a blast phase or crisis (transformation to acute leukemia).

Epidemiology

Incidence
  • Per year, 1.6 cases/100,000 persons
  • Predominant age: 50 to 60 years
  • Predominant sex: male > female (1.3:1)

Prevalence
Accounts for 15–20% of adult leukemias

Etiology and Pathophysiology

Philadelphia chromosome is a balanced translocation between BCR (on chromosome 22) and ABL (on chromosome 9) genes t(9;22)(q34;q11). This fusion gene, BCR-ABL, codes for an abnormal, constitutively active tyrosine kinase that affects numerous signal transduction pathways, resulting in uncontrolled cell proliferation and reduced apoptosis.

Genetics
Acquired genomic changes

Risk Factors

Ionizing radiation exposure (uncommon)

General Prevention

None currently identified

-- To view the remaining sections of this topic, please or purchase a subscription --